The Pew Charitable Trusts has tracked the pipeline of antibiotics in clinical development since 2014 and has aggregated updates into an interactive tool that illustrates trends in the pipeline—as drugs are either approved, discontinued from development, or remain stagnant. This longitudinal assessment underscores the long-standing concerns of scientists, doctors, public health officials, and other stakeholders regarding the dangerously low number of antibiotics in development to address current and future patient needs, particularly for treating the most urgent bacterial threats, such as Gram-negative pathogens, and those prioritized by the Centers for Disease Control and Prevention and the World Health Organization.

Click the play button to see the evolution of the antibiotic pipeline since 2014, or click on an individual year to see the status of the pipeline at a particular point in time. (To view without animation, uncheck the “animate change” box.) To see additional information about each drug, hover over or tap any of the rectangles.

Visually impaired users may wish to skip to the summary of the content.

Antibiotics in Development Since 2014

Antibiotic

Expected to treat CDC urgent pathogen

Novel antibiotics

Expected to treat Gram-negative ESKAPE pathogens

PHASE 1P1
PHASE 2P2
PHASE 3P3
APPLICATIONNDA
APPROVED

Total approved antibiotics since 2014: 4

Total discontinued antibiotics since 2014: 6

2014

Phase 1

Active

  • Afabicin (Debio 1450) (Debiopharm International SA)
  • BAL30072 (Basilea Pharmaceutica Ltd.)
  • CRS3123 (Crestone Inc.)
  • Delpazolid (LCB01-0371) (LegoChem Biosciences Inc. (Shanghai HaiHe Pharmaceutical Co., Ltd./ CSPC Pharmaceutical Group Ltd. licensees))
  • Meropenem + nacubactam (OP0595/ RG6080) (Meiji Seika Pharma Co. Ltd./ Fedora Pharmaceuticals Inc.)
  • Contezolid (MRX-I) & contezolid acefosamil (MRX-4) (MicuRx Pharmaceuticals Inc.)
  • TD-1607 (Theravance Biopharma Inc.)
  • WCK 771/ WCK 2349 (levonadifloxacin, alalevonadifloxacin) (Wockhardt Ltd.)

Inactive

  • ACHN-975 (Achaogen Inc.)
  • EDP-788 (Enanta Pharmaceuticals Inc.)

Phase 2

Active

  • Avarofloxacin (Allergan PLC (formerly Actavis PLC))
  • Brilacidin (Innovation Pharmaceuticals Inc.)
  • Fetroja (cefiderocol) (Shionogi & Co. Ltd.)
  • Ceftaroline + avibactam (AstraZeneca PLC/ Forest Laboratories Inc.)
  • CG-549 (CrystalGenomics Inc.)
  • Finafloxacin (MerLion Pharmaceuticals GmbH)
  • Gepotidacin (GSK2140944) (GlaxoSmithKline PLC)
  • Recarbrio (imipenem/ cilastatin + relebactam) (Merck & Co. Inc.)
  • Xenleta (lefamulin) (Nabriva Therapeutics PLC)
  • Murepavadin (POL7080) (Polyphor AG)
  • Taigexyn (nemonoxacin) (TaiGen Biotechnology Co. Ltd.)
  • Nuzyra (omadacycline) (Paratek Pharmaceuticals Inc.)
  • Radezolid (Melinta Therapeutics Inc.)
  • Ramoplanin (Nanotherapeutics Inc.)
  • Ridinilazole (Summit Therapeutics PLC)
  • Zabofloxacin (Dong Wha Pharmaceutical Co. Ltd.)
  • Zoliflodacin (ETX0914) (Entasis Therapeutics Inc.)

Inactive

  • Cefilavacin (R-Pharm)
  • GSK-1322322 (GlaxoSmithKline PLC)
  • LFF571 (Novartis AG)

Phase 3

Active

  • Baxdela (delafloxacin) (Melinta Therapeutics Inc.)
  • Cadazolid (Actelion Pharmaceuticals Ltd.)
  • Xerava (eravacycline) (Tetraphase Pharmaceuticals Inc.)
  • Zemdri (plazomicin) (Achaogen Inc.)
  • T-4288 (solithromycin) (Toyama Chemical Co. Ltd.)
  • Surotomycin (Merck & Co. Inc. (formerly Cubist Pharmaceuticals Inc.))
  • ARV-1801 (fusidic acid) (Arrevus Inc.)
  • Vabomere (meropenem + vaborbactam) (The Medicines Company)

Inactive

  • Ceftobiprole (Basilea Pharmaceutica Ltd.)

New drug application

Active

  • Avycaz (ceftazidime + avibactam) (AstraZeneca PLC/ Actavis PLC)

Inactive

    Approved

    Active

    • Dalvance (dalbavancin) (Durata Therapeutics Inc.)
    • Orbactiv (oritavancin) (The Medicines Company)
    • Sivextro (tedizolid) (Cubist Pharmaceuticals Inc.)
    • Zerbaxa (ceftolozane + tazobactam) (Cubist Pharmaceuticals Inc.)

    Inactive

      2015

      Phase 1

      Active

      • BAL30072 (Basilea Pharmaceutica Ltd.)
      • CRS3123 (Crestone Inc.)
      • Delpazolid (LCB01-0371) (LegoChem Biosciences Inc. (Shanghai HaiHe Pharmaceutical Co., Ltd./ CSPC Pharmaceutical Group Ltd. licensees))
      • Meropenem + nacubactam (OP0595/ RG6080) (Meiji Seika Pharma Co. Ltd./ Fedora Pharmaceuticals Inc.)
      • MGB-BP-3 (MGB Biopharma Ltd.)
      • Nafithromycin (WCK 4873) (Wockhardt Ltd.)
      • TD-1607 (Theravance Biopharma Inc.)
      • WCK 771/ WCK 2349 (levonadifloxacin, alalevonadifloxacin) (Wockhardt Ltd.)

      Inactive

      • ACHN-975 (Achaogen Inc.)
      • EDP-788 (Enanta Pharmaceuticals Inc.)

      Phase 2

      Active

      • Afabicin (Debio 1450) (Debiopharm International SA)
      • Avarofloxacin (Allergan PLC (formerly Actavis PLC))
      • Brilacidin (Innovation Pharmaceuticals Inc.)
      • Fetroja (cefiderocol) (Shionogi & Co. Ltd.)
      • Ceftaroline + avibactam (AstraZeneca PLC/ Forest Laboratories Inc.)
      • CG-549 (CrystalGenomics Inc.)
      • Finafloxacin (MerLion Pharmaceuticals GmbH)
      • Gepotidacin (GSK2140944) (GlaxoSmithKline PLC)
      • Contezolid (MRX-I) & contezolid acefosamil (MRX-4) (MicuRx Pharmaceuticals Inc.)
      • Murepavadin (POL7080) (Polyphor AG)
      • Taigexyn (nemonoxacin) (TaiGen Biotechnology Co. Ltd.)
      • Radezolid (Melinta Therapeutics Inc.)
      • Ramoplanin (Nanotherapeutics Inc.)
      • Ridinilazole (Summit Therapeutics PLC)
      • Zabofloxacin (Dong Wha Pharmaceutical Co. Ltd.)
      • Zoliflodacin (ETX0914) (Entasis Therapeutics Inc.)

      Inactive

      • Cefilavacin (R-Pharm)
      • GSK-1322322 (GlaxoSmithKline PLC)
      • LFF571 (Novartis AG)

      Phase 3

      Active

      • Baxdela (delafloxacin) (Melinta Therapeutics Inc.)
      • Cadazolid (Actelion Pharmaceuticals Ltd.)
      • Xerava (eravacycline) (Tetraphase Pharmaceuticals Inc.)
      • Iclaprim (Motif Bio PLC)
      • Recarbrio (imipenem/ cilastatin + relebactam) (Merck & Co. Inc.)
      • Xenleta (lefamulin) (Nabriva Therapeutics PLC)
      • Nuzyra (omadacycline) (Paratek Pharmaceuticals Inc.)
      • Zemdri (plazomicin) (Achaogen Inc.)
      • T-4288 (solithromycin) (Toyama Chemical Co. Ltd.)
      • Surotomycin (Merck & Co. Inc. (formerly Cubist Pharmaceuticals Inc.))
      • ARV-1801 (fusidic acid) (Arrevus Inc.)
      • Vabomere (meropenem + vaborbactam) (The Medicines Company)

      Inactive

      • Ceftobiprole (Basilea Pharmaceutica Ltd.)

      New drug application

      Active

        Inactive

          Approved

          Active

          • Avycaz (ceftazidime + avibactam) (AstraZeneca PLC/ Actavis PLC)
          • Dalvance (dalbavancin) (Durata Therapeutics Inc.)
          • Orbactiv (oritavancin) (The Medicines Company)
          • Sivextro (tedizolid) (Cubist Pharmaceuticals Inc.)
          • Zerbaxa (ceftolozane + tazobactam) (Cubist Pharmaceuticals Inc.)

          Inactive

            2016

            Phase 1

            Active

            • WCK 5222 (cefepime + zidebactam) (Wockhardt Ltd.)
            • CRS3123 (Crestone Inc.)
            • Delpazolid (LCB01-0371) (LegoChem Biosciences Inc. (Shanghai HaiHe Pharmaceutical Co., Ltd./ CSPC Pharmaceutical Group Ltd. licensees))
            • GSK-3342830 (GlaxoSmithKline PLC (Shionogi licensee))
            • KBP-7072 (KBP BioSciences Pharmaceutical Technical Co. Ltd.)
            • DNV3837/ DNV3681 (Deinove SA)
            • Meropenem + nacubactam (OP0595/ RG6080) (Meiji Seika Pharma Co. Ltd./ Fedora Pharmaceuticals Inc.)
            • MGB-BP-3 (MGB Biopharma Ltd.)
            • Nafithromycin (WCK 4873) (Wockhardt Ltd.)
            • TD-1607 (Theravance Biopharma Inc.)
            • TP-271 (Tetraphase Pharmaceuticals Inc.)
            • TP-6076 (Tetraphase Pharmaceuticals Inc.)
            • WCK 771/ WCK 2349 (levonadifloxacin, alalevonadifloxacin) (Wockhardt Ltd.)

            Inactive

            • ACHN-975 (Achaogen Inc.)
            • BAL30072 (Basilea Pharmaceutica Ltd.)
            • EDP-788 (Enanta Pharmaceuticals Inc.)

            Phase 2

            Active

            • Afabicin (Debio 1450) (Debiopharm International SA)
            • Brilacidin (Innovation Pharmaceuticals Inc.)
            • Ceftaroline + avibactam (AstraZeneca PLC/ Forest Laboratories Inc.)
            • CG-549 (CrystalGenomics Inc.)
            • Finafloxacin (MerLion Pharmaceuticals GmbH)
            • Gepotidacin (GSK2140944) (GlaxoSmithKline PLC)
            • Contezolid (MRX-I) & contezolid acefosamil (MRX-4) (MicuRx Pharmaceuticals Inc.)
            • Murepavadin (POL7080) (Polyphor AG)
            • Taigexyn (nemonoxacin) (TaiGen Biotechnology Co. Ltd.)
            • Ramoplanin (Nanotherapeutics Inc.)
            • Ridinilazole (Summit Therapeutics PLC)
            • Zoliflodacin (ETX0914) (Entasis Therapeutics Inc.)

            Inactive

            • Avarofloxacin (Allergan PLC (formerly Actavis PLC))
            • Cefilavacin (R-Pharm)
            • GSK-1322322 (GlaxoSmithKline PLC)
            • LFF571 (Novartis AG)
            • Radezolid (Melinta Therapeutics Inc.)

            Phase 3

            Active

            • Cadazolid (Actelion Pharmaceuticals Ltd.)
            • Fetroja (cefiderocol) (Shionogi & Co. Ltd.)
            • Xerava (eravacycline) (Tetraphase Pharmaceuticals Inc.)
            • Iclaprim (Motif Bio PLC)
            • Recarbrio (imipenem/ cilastatin + relebactam) (Merck & Co. Inc.)
            • Xenleta (lefamulin) (Nabriva Therapeutics PLC)
            • Nuzyra (omadacycline) (Paratek Pharmaceuticals Inc.)
            • Zemdri (plazomicin) (Achaogen Inc.)
            • ARV-1801 (fusidic acid) (Arrevus Inc.)
            • Vabomere (meropenem + vaborbactam) (The Medicines Company)
            • Zabofloxacin (Dong Wha Pharmaceutical Co. Ltd.)

            Inactive

            • Ceftobiprole (Basilea Pharmaceutica Ltd.)
            • Surotomycin (Merck & Co. Inc. (formerly Cubist Pharmaceuticals Inc.))

            New drug application

            Active

            • Baxdela (delafloxacin) (Melinta Therapeutics Inc.)
            • T-4288 (solithromycin) (Toyama Chemical Co. Ltd.)

            Inactive

              Approved

              Active

              • Avycaz (ceftazidime + avibactam) (AstraZeneca PLC/ Actavis PLC)
              • Dalvance (dalbavancin) (Durata Therapeutics Inc.)
              • Orbactiv (oritavancin) (The Medicines Company)
              • Sivextro (tedizolid) (Cubist Pharmaceuticals Inc.)
              • Zerbaxa (ceftolozane + tazobactam) (Cubist Pharmaceuticals Inc.)

              Inactive

                2017

                Phase 1

                Active

                • AIC499 (AiCuris Anti-infective Cures GmbH)
                • Cefepime + taniborbactam (VNRX-5133) (Venatorx Pharmaceuticals Inc.)
                • WCK 5222 (cefepime + zidebactam) (Wockhardt Ltd.)
                • CRS3123 (Crestone Inc.)
                • Delpazolid (LCB01-0371) (LegoChem Biosciences Inc. (Shanghai HaiHe Pharmaceutical Co., Ltd./ CSPC Pharmaceutical Group Ltd. licensees))
                • DS-2969 (Daiichi Sankyo Co., Ltd.)
                • Sulbactam + durlobactam (Entasis Therapeutics Inc.)
                • GSK-3342830 (GlaxoSmithKline PLC (Shionogi licensee))
                • KBP-7072 (KBP BioSciences Pharmaceutical Technical Co. Ltd.)
                • DNV3837/ DNV3681 (Deinove SA)
                • Meropenem + nacubactam (OP0595/ RG6080) (Meiji Seika Pharma Co. Ltd./ Fedora Pharmaceuticals Inc.)
                • MGB-BP-3 (MGB Biopharma Ltd.)
                • SPR741 (Spero Therapeutics Inc.)
                • Tebipenem/ tebipenem pivoxil hydrobromide (Spero Therapeutics Inc.)
                • TP-271 (Tetraphase Pharmaceuticals Inc.)
                • TP-6076 (Tetraphase Pharmaceuticals Inc.)

                Inactive

                • ACHN-975 (Achaogen Inc.)
                • BAL30072 (Basilea Pharmaceutica Ltd.)
                • EDP-788 (Enanta Pharmaceuticals Inc.)
                • TD-1607 (Theravance Biopharma Inc.)

                Phase 2

                Active

                • Afabicin (Debio 1450) (Debiopharm International SA)
                • BOS-228 (Boston Pharmaceuticals Inc.)
                • Brilacidin (Innovation Pharmaceuticals Inc.)
                • Cefepime + enmetazobactam (Allecra Therapeutics GmbH)
                • CG-549 (CrystalGenomics Inc.)
                • Finafloxacin (MerLion Pharmaceuticals GmbH)
                • Gepotidacin (GSK2140944) (GlaxoSmithKline PLC)
                • Murepavadin (POL7080) (Polyphor AG)
                • Nafithromycin (WCK 4873) (Wockhardt Ltd.)
                • Taigexyn (nemonoxacin) (TaiGen Biotechnology Co. Ltd.)
                • OPS-2071 (Otsuka Pharmaceutical Co. Ltd.)
                • Ridinilazole (Summit Therapeutics PLC)
                • WCK 771/ WCK 2349 (levonadifloxacin, alalevonadifloxacin) (Wockhardt Ltd.)
                • Zoliflodacin (ETX0914) (Entasis Therapeutics Inc.)

                Inactive

                • Avarofloxacin (Allergan PLC (formerly Actavis PLC))
                • Ceftaroline + avibactam (AstraZeneca PLC/ Forest Laboratories Inc.)
                • GSK-1322322 (GlaxoSmithKline PLC)
                • LFF571 (Novartis AG)
                • Radezolid (Melinta Therapeutics Inc.)
                • Ramoplanin (Nanotherapeutics Inc.)

                Phase 3

                Active

                • Cadazolid (Actelion Pharmaceuticals Ltd.)
                • Fetroja (cefiderocol) (Shionogi & Co. Ltd.)
                • Cefilavacin (R-Pharm)
                • Ceftobiprole (Basilea Pharmaceutica Ltd.)
                • Xerava (eravacycline) (Tetraphase Pharmaceuticals Inc.)
                • Iclaprim (Motif Bio PLC)
                • Recarbrio (imipenem/ cilastatin + relebactam) (Merck & Co. Inc.)
                • Lasvic (lascufloxacin) (Kyorin Pharmaceutical Co. Ltd.)
                • Xenleta (lefamulin) (Nabriva Therapeutics PLC)
                • Contezolid (MRX-I) & contezolid acefosamil (MRX-4) (MicuRx Pharmaceuticals Inc.)
                • Nuzyra (omadacycline) (Paratek Pharmaceuticals Inc.)
                • T-4288 (solithromycin) (Toyama Chemical Co. Ltd.)
                • Sulopenem/ sulopenem- etzadroxil- probenecid (Iterum Therapeutics PLC)
                • ARV-1801 (fusidic acid) (Arrevus Inc.)
                • Zabofloxacin (Dong Wha Pharmaceutical Co. Ltd.)

                Inactive

                • Surotomycin (Merck & Co. Inc. (formerly Cubist Pharmaceuticals Inc.))

                New drug application

                Active

                • Zemdri (plazomicin) (Achaogen Inc.)

                Inactive

                  Approved

                  Active

                  • Avycaz (ceftazidime + avibactam) (AstraZeneca PLC/ Actavis PLC)
                  • Baxdela (delafloxacin) (Melinta Therapeutics Inc.)
                  • Dalvance (dalbavancin) (Durata Therapeutics Inc.)
                  • Orbactiv (oritavancin) (The Medicines Company)
                  • Sivextro (tedizolid) (Cubist Pharmaceuticals Inc.)
                  • Vabomere (meropenem + vaborbactam) (The Medicines Company)
                  • Zerbaxa (ceftolozane + tazobactam) (Cubist Pharmaceuticals Inc.)

                  Inactive

                    2018

                    Phase 1

                    Active

                    • Ibezapolstat (ACX-362E) (Acurx Pharmaceuticals LLC)
                    • AIC499 (AiCuris Anti-infective Cures GmbH)
                    • Cefepime + taniborbactam (VNRX-5133) (Venatorx Pharmaceuticals Inc.)
                    • WCK 5222 (cefepime + zidebactam) (Wockhardt Ltd.)
                    • CRS3123 (Crestone Inc.)
                    • Delpazolid (LCB01-0371) (LegoChem Biosciences Inc. (Shanghai HaiHe Pharmaceutical Co., Ltd./ CSPC Pharmaceutical Group Ltd. licensees))
                    • ETX0282CPDP/ ETX1317 (Entasis Therapeutics Inc.)
                    • KBP-7072 (KBP BioSciences Pharmaceutical Technical Co. Ltd.)
                    • DNV3837/ DNV3681 (Deinove SA)
                    • Meropenem + nacubactam (OP0595/ RG6080) (Meiji Seika Pharma Co. Ltd./ Fedora Pharmaceuticals Inc.)
                    • MGB-BP-3 (MGB Biopharma Ltd.)
                    • SPR206 (Spero Therapeutics Inc.)
                    • SPR741 (Spero Therapeutics Inc.)
                    • TP-271 (Tetraphase Pharmaceuticals Inc.)
                    • TP-6076 (Tetraphase Pharmaceuticals Inc.)

                    Inactive

                    • ACHN-975 (Achaogen Inc.)
                    • BAL30072 (Basilea Pharmaceutica Ltd.)
                    • DS-2969 (Daiichi Sankyo Co., Ltd.)
                    • EDP-788 (Enanta Pharmaceuticals Inc.)
                    • GSK-3342830 (GlaxoSmithKline PLC (Shionogi licensee))
                    • TD-1607 (Theravance Biopharma Inc.)

                    Phase 2

                    Active

                    • Afabicin (Debio 1450) (Debiopharm International SA)
                    • BOS-228 (Boston Pharmaceuticals Inc.)
                    • Brilacidin (Innovation Pharmaceuticals Inc.)
                    • CG-549 (CrystalGenomics Inc.)
                    • Sulbactam + durlobactam (Entasis Therapeutics Inc.)
                    • Finafloxacin (MerLion Pharmaceuticals GmbH)
                    • Gepotidacin (GSK2140944) (GlaxoSmithKline PLC)
                    • Nafithromycin (WCK 4873) (Wockhardt Ltd.)
                    • Taigexyn (nemonoxacin) (TaiGen Biotechnology Co. Ltd.)
                    • OPS-2071 (Otsuka Pharmaceutical Co. Ltd.)
                    • Zoliflodacin (ETX0914) (Entasis Therapeutics Inc.)

                    Inactive

                    • Avarofloxacin (Allergan PLC (formerly Actavis PLC))
                    • Ceftaroline + avibactam (AstraZeneca PLC/ Forest Laboratories Inc.)
                    • GSK-1322322 (GlaxoSmithKline PLC)
                    • LFF571 (Novartis AG)
                    • Radezolid (Melinta Therapeutics Inc.)
                    • Ramoplanin (Nanotherapeutics Inc.)

                    Phase 3

                    Active

                    • Cefepime + enmetazobactam (Allecra Therapeutics GmbH)
                    • Fetroja (cefiderocol) (Shionogi & Co. Ltd.)
                    • Cefilavacin (R-Pharm)
                    • Ceftobiprole (Basilea Pharmaceutica Ltd.)
                    • Recarbrio (imipenem/ cilastatin + relebactam) (Merck & Co. Inc.)
                    • Contezolid (MRX-I) & contezolid acefosamil (MRX-4) (MicuRx Pharmaceuticals Inc.)
                    • Murepavadin (POL7080) (Polyphor AG)
                    • Ridinilazole (Summit Therapeutics PLC)
                    • T-4288 (solithromycin) (Toyama Chemical Co. Ltd.)
                    • Tebipenem/ tebipenem pivoxil hydrobromide (Spero Therapeutics Inc.)
                    • Sulopenem/ sulopenem- etzadroxil- probenecid (Iterum Therapeutics PLC)
                    • ARV-1801 (fusidic acid) (Arrevus Inc.)
                    • WCK 771/ WCK 2349 (levonadifloxacin, alalevonadifloxacin) (Wockhardt Ltd.)

                    Inactive

                    • Cadazolid (Actelion Pharmaceuticals Ltd.)
                    • Surotomycin (Merck & Co. Inc. (formerly Cubist Pharmaceuticals Inc.))
                    • Zabofloxacin (Dong Wha Pharmaceutical Co. Ltd.)

                    New drug application

                    Active

                    • Iclaprim (Motif Bio PLC)
                    • Lasvic (lascufloxacin) (Kyorin Pharmaceutical Co. Ltd.)
                    • Xenleta (lefamulin) (Nabriva Therapeutics PLC)

                    Inactive

                      Approved

                      Active

                      • Avycaz (ceftazidime + avibactam) (AstraZeneca PLC/ Actavis PLC)
                      • Baxdela (delafloxacin) (Melinta Therapeutics Inc.)
                      • Dalvance (dalbavancin) (Durata Therapeutics Inc.)
                      • Xerava (eravacycline) (Tetraphase Pharmaceuticals Inc.)
                      • Nuzyra (omadacycline) (Paratek Pharmaceuticals Inc.)
                      • Orbactiv (oritavancin) (The Medicines Company)
                      • Zemdri (plazomicin) (Achaogen Inc.)
                      • Sivextro (tedizolid) (Cubist Pharmaceuticals Inc.)
                      • Vabomere (meropenem + vaborbactam) (The Medicines Company)
                      • Zerbaxa (ceftolozane + tazobactam) (Cubist Pharmaceuticals Inc.)

                      Inactive

                        2019

                        Phase 1

                        Active

                        • Ibezapolstat (ACX-362E) (Acurx Pharmaceuticals LLC)
                        • WCK 5222 (cefepime + zidebactam) (Wockhardt Ltd.)
                        • CRS3123 (Crestone Inc.)
                        • Delpazolid (LCB01-0371) (LegoChem Biosciences Inc. (Shanghai HaiHe Pharmaceutical Co., Ltd./ CSPC Pharmaceutical Group Ltd. licensees))
                        • ETX0282CPDP/ ETX1317 (Entasis Therapeutics Inc.)
                        • KBP-7072 (KBP BioSciences Pharmaceutical Technical Co. Ltd.)
                        • Meropenem + nacubactam (OP0595/ RG6080) (Meiji Seika Pharma Co. Ltd./ Fedora Pharmaceuticals Inc.)
                        • SPR206 (Spero Therapeutics Inc.)
                        • SPR741 (Spero Therapeutics Inc.)
                        • TP-271 (Tetraphase Pharmaceuticals Inc.)
                        • TP-6076 (Tetraphase Pharmaceuticals Inc.)
                        • Apramycin (Juvabis AG)
                        • Oravance (QPX-2015 + QPX-7728) (Qpex Biopharma/ Brii Biosciences)
                        • TXA709/ TXA707 (Taxis Pharmaceuticals Inc.)
                        • VNRX-7145 + ceftibuten (Venatorx Pharmaceuticals Inc.)

                        Inactive

                        • ACHN-975 (Achaogen Inc.)
                        • AIC499 (AiCuris Anti-infective Cures GmbH)
                        • BAL30072 (Basilea Pharmaceutica Ltd.)
                        • DS-2969 (Daiichi Sankyo Co., Ltd.)
                        • EDP-788 (Enanta Pharmaceuticals Inc.)
                        • GSK-3342830 (GlaxoSmithKline PLC (Shionogi licensee))
                        • TD-1607 (Theravance Biopharma Inc.)

                        Phase 2

                        Active

                        • Afabicin (Debio 1450) (Debiopharm International SA)
                        • BOS-228 (Boston Pharmaceuticals Inc.)
                        • Brilacidin (Innovation Pharmaceuticals Inc.)
                        • CG-549 (CrystalGenomics Inc.)
                        • Finafloxacin (MerLion Pharmaceuticals GmbH)
                        • DNV3837/ DNV3681 (Deinove SA)
                        • MGB-BP-3 (MGB Biopharma Ltd.)
                        • Nafithromycin (WCK 4873) (Wockhardt Ltd.)
                        • Taigexyn (nemonoxacin) (TaiGen Biotechnology Co. Ltd.)
                        • ARV-1801 (fusidic acid) (Arrevus Inc.)
                        • Benapenem (Sihuan Pharmaceutical Co. Ltd.)
                        • TNP-2092 (TenNor Therapeutics Ltd.)

                        Inactive

                        • Avarofloxacin (Allergan PLC (formerly Actavis PLC))
                        • Ceftaroline + avibactam (AstraZeneca PLC/ Forest Laboratories Inc.)
                        • GSK-1322322 (GlaxoSmithKline PLC)
                        • LFF571 (Novartis AG)
                        • OPS-2071 (Otsuka Pharmaceutical Co. Ltd.)
                        • Radezolid (Melinta Therapeutics Inc.)
                        • Ramoplanin (Nanotherapeutics Inc.)

                        Phase 3

                        Active

                        • Cefepime + enmetazobactam (Allecra Therapeutics GmbH)
                        • Cefepime + taniborbactam (VNRX-5133) (Venatorx Pharmaceuticals Inc.)
                        • Cefilavacin (R-Pharm)
                        • Ceftobiprole (Basilea Pharmaceutica Ltd.)
                        • Sulbactam + durlobactam (Entasis Therapeutics Inc.)
                        • Gepotidacin (GSK2140944) (GlaxoSmithKline PLC)
                        • Iclaprim (Motif Bio PLC)
                        • Contezolid (MRX-I) & contezolid acefosamil (MRX-4) (MicuRx Pharmaceuticals Inc.)
                        • Ridinilazole (Summit Therapeutics PLC)
                        • T-4288 (solithromycin) (Toyama Chemical Co. Ltd.)
                        • Tebipenem/ tebipenem pivoxil hydrobromide (Spero Therapeutics Inc.)
                        • Sulopenem/ sulopenem- etzadroxil- probenecid (Iterum Therapeutics PLC)
                        • Zoliflodacin (ETX0914) (Entasis Therapeutics Inc.)

                        Inactive

                        • Cadazolid (Actelion Pharmaceuticals Ltd.)
                        • Murepavadin (POL7080) (Polyphor AG)
                        • Surotomycin (Merck & Co. Inc. (formerly Cubist Pharmaceuticals Inc.))
                        • Zabofloxacin (Dong Wha Pharmaceutical Co. Ltd.)

                        New drug application

                        Active

                        • WCK 771/ WCK 2349 (levonadifloxacin, alalevonadifloxacin) (Wockhardt Ltd.)

                        Inactive

                          Approved

                          Active

                          • Avycaz (ceftazidime + avibactam) (AstraZeneca PLC/ Actavis PLC)
                          • Baxdela (delafloxacin) (Melinta Therapeutics Inc.)
                          • Fetroja (cefiderocol) (Shionogi & Co. Ltd.)
                          • Dalvance (dalbavancin) (Durata Therapeutics Inc.)
                          • Xerava (eravacycline) (Tetraphase Pharmaceuticals Inc.)
                          • Recarbrio (imipenem/ cilastatin + relebactam) (Merck & Co. Inc.)
                          • Lasvic (lascufloxacin) (Kyorin Pharmaceutical Co. Ltd.)
                          • Xenleta (lefamulin) (Nabriva Therapeutics PLC)
                          • Nuzyra (omadacycline) (Paratek Pharmaceuticals Inc.)
                          • Orbactiv (oritavancin) (The Medicines Company)
                          • Zemdri (plazomicin) (Achaogen Inc.)
                          • Sivextro (tedizolid) (Cubist Pharmaceuticals Inc.)
                          • Vabomere (meropenem + vaborbactam) (The Medicines Company)
                          • Zerbaxa (ceftolozane + tazobactam) (Cubist Pharmaceuticals Inc.)

                          Inactive

                            Notes: Candidates included in this data visualization are consistent with Pew’s methodology for tracking antibiotics in clinical development. The analysis captures the status of antibiotics in the pipeline beginning in 2014, including those approved by the FDA and other regulatory agencies that year. More information about methodology and the full underlying data can be found in Pew’s latest pipeline analysis. This interactive tool is updated annually.